GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Indegene Ltd (BOM:544172) » Definitions » ROCE %

Indegene (BOM:544172) ROCE % : 23.78% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Indegene ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Indegene's annualized ROCE % for the quarter that ended in Dec. 2024 was 23.78%.


Indegene ROCE % Historical Data

The historical data trend for Indegene's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indegene ROCE % Chart

Indegene Annual Data
Trend Mar21 Mar22 Mar23 Mar24
ROCE %
68.23 35.30 30.01 27.84

Indegene Quarterly Data
Mar21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 30.82 30.62 27.15 20.38 23.78

Indegene ROCE % Calculation

Indegene's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=5080/( ( (22038.66 - 4891.46) + (25456 - 6109) )/ 2 )
=5080/( (17147.2+19347)/ 2 )
=5080/18247.1
=27.84 %

Indegene's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=5980/( ( (30241 - 5099) + (0 - 0) )/ 1 )
=5980/( ( 25142 + 0 )/ 1 )
=5980/25142
=23.78 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Indegene  (BOM:544172) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Indegene ROCE % Related Terms

Thank you for viewing the detailed overview of Indegene's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Indegene Business Description

Traded in Other Exchanges
Address
Outer Ring Road, Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Nagawara, Bengaluru, KA, IND, 560045
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment.

Indegene Headlines

No Headlines